Covid-19 Expediting the Healthcare Industry like Never Before?


Date : Sep 04, 2020 Author : PMR Editorial Staff Category : Healthcare

Influenza (flu) comes across as a kind of contagious respiratory infection. As such, it adversely affects the respiratory track, i.e. lungs, throat, and nose of humans.

Covid-19 Expediting the Healthcare Industry like Never Before?

Influenza (flu) comes across as a kind of contagious respiratory infection. As such, it adversely affects the respiratory track, i.e. lungs, throat, and nose of humans. The common symptoms are inclusive of headache, cough, runny nose, fever, severe weakness, and muscle pain. The WHO states that the year 2018 marked hospitalization of more than 5 Mn individuals due to influenza and more than 0.2 Mn deaths on the same count.

Moreover, the CDC Report 2019 stated that 91 children died of flu in 2018. The 3 flu seasons witnessed previously has registered 95, 110, and 185 pediatric fatalities respectively. As such, the flu vaccine, better known as “flu shot” or “flu jab”, is expected to witness an explosive demand between 2020 and 2030. So, it could be inferred that the flu vaccine market is expected to witness geometric progression between 2020 and 2030.

Flu and Covid-19: Similar?

The outbreak of Covid-19 has given an impetus to flu testing across the globe. This could be attributed to the fact that both – flu and Covid-19 infect the respiratory track. Plus, both the viruses get transmitted through droplets and fomites. The first stage symptoms are also the same.

However, the basic difference herein is the speed at which the two virus get transmitted. Covid-19 virus is reported to have a longer incubation period in comparison with flu. Also, Covid-19 has got higher mortality rate than flu. This is evident from the 25,933,731 cases reported worldwide till date.

What Calls for Vaccines?

Contagious diseases could be treated with medicines, but till the time (atleast 24 hours) the medicine shows its positivities, the same diseases are bound to encompass more number of people. It’s here that vaccines come into picture. The antibodies produced ascertain immunity.

Likewise, the prevalence of contagious diseases is witnessing the propagation of autogenous vaccines and meningococcal vaccines. Contagious diseases are likely to cause severe disturbance to livestock production, which could affect humans health-wise as well as on monetary count. As per Persistence Market Research, the global autogenous vaccines market is expected to witness a CAGR of 4.4% from 2020 to 2030.

Meningococcal vaccines are under trial. For instance – the US FDA has agreed upon reviewing MenQuadfi, meningococcal vaccine candidate from Sanofi. Though meningococcal meningitis is looked upon as a rare ailment, the disastrous effect can’t be ignored. Research states that even though the fatality rate is 10%, the survivors also don’t get spared. In other words, deafness, brain damage, and/or amputation could be seen in survivors. This makes tabling meningococcal vaccines imperative.

In a nutshell, be it a contagious disease or a rarely occurring disease, having vaccines on board is mandatory.

Is influenza vaccine effective in combating Covid-19?

The medical fraternity has confirmed that influenza vaccines are not completely effective in prevention of coronavirus. In fact, it has been found that the ones who received 3-strain flu vaccine were more susceptible to Coronavirus.

Covid-19 vaccine in Making?

Innovations are being triggered in flu shots to subvert Covid-19. For example – of late, Bharat Biotech, with University of Wisconsin Madison and FluGen have started experimenting with the flu vaccines for fighting off Coronavirus. Nasal drop vaccine candidates are drawing the attention of healthcare personnel in India. The organizations are into collaboration with virologists for developing nasal drop vaccines having proper vaccines.

As of now, more than 170 vaccine groups are working on the development of an effective vaccine for Covid-19. However, only some of these have reached the critical phase of development. Amongst them, Covaxin is well-prepared to make an entry to mid-scale phase II trials.

AstraZeneca, into partnership with the University of Oxford, has entered the 3rd phase of critical trials in the US. Oxford University has begun with dosing volunteers with the shots of AZD-1222 vaccine (branded as Covishield). It is in phase II/III. Serum Institute, India has selected more than 17 sites wherein almost 1600 volunteers would be involved in first round.

Pfizer is also into development of Covid-19 vaccine on inking a partnership with BionTech. It is also in phase-III trials.

The first Vaccine for Covid-19 Registered in Russia?

Russia holds the distinction of becoming the first country to successfully register Covid-19 vaccine, which has been earmarked as “Sputnik V”. The very first group of the volunteers are being dosed.

Safety of Moderna Vaccine

For high-risk categories, safety of the vaccines mentioned above is to be pondered about. However, Moderna that is working on development of an mRNA vaccine has gone ahead with proving that its “vaccine candidate” is safe for the elder people.


Back To Top